Investigational drug · Phase 3
Hepalatide
Also called: L47, HLT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatitis D, Chronic, Hepatitis D.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "Hepalatide"
First trial start
2024
Dec 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Hepalatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatitis D, Chronic
- Hepatitis D
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Hepalatide" as an intervention, largest first.
- Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DPivotal-lookingNot yet recruiting
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT07309380 · 150 participants (planned) · Start Jun 2027 · Primary completion Jun 2028
Drug: Hepalatide 2.1mg; Placebo of Hepalatide · For: Hepatitis D, Chronic
Sites: Changchun, China
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT04426968 · 96 participants · Start Jun 18, 2021 · Primary completion Nov 1, 2023
Drug: Hepalatide 2.1mg; Hepalatide 4.2mg and 5 more · For: Hepatitis B, Chronic
Sites: Beijing, China; Changchun, China; Chizhou, China · 12 sites in all
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT06505928 · 90 participants · Start Dec 11, 2024 · Primary completion May 1, 2026
Drug: hepalatide · For: Hepatitis D
Sites: Ulaanbaatar, Mongolia · 2 sites in all
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT02612506 · 48 participants · Start Oct 2015 · Primary completion Aug 2016
Drug: Hepalatide; Placebo · For: Hepatitis B, Chronic
Sites: Beijing, China
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT03023787 · 35 participants · Start Aug 2016 · Primary completion Dec 2016
Drug: Hepalatide; Placebo · For: Hepatitis B, Chronic
Sites: Beijing, China
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT05827146 · 23 participants · Start Oct 7, 2023 · Primary completion Jan 30, 2024
Drug: Hepalatide; Hepalatide Placebo · For: Chronic Hepatitis D Infection
Sites: Ürümqi, China; Changchun, China; Ulaanbaatar, Mongolia
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT05244057 · 8 participants · Start Aug 23, 2022 · Primary completion Jun 24, 2024
Drug: Hepalatide; Placebo of Hepalatide and 2 more · For: Chronic Hepatitis B
Sites: Shanghai, China
Shanghai HEP Pharmaceutical Co., Ltd.Industry
NCT04662164 · 0 participants · Start Dec 2025 · Primary completion Dec 2025
Drug: hepalatide · For: Type 2 Diabetes Patients
Newest research
PubMed records naming it or its code names, newest first.
- Dihydroquercetin derived from Huanglong Decoction improves acute pancreatitis and related intestinal damage through STAT3/ERK/ZBP1 pathway.
Ran S, Pan L, Sun C, et al. · Eur J Pharmacol 2026
- Risk factors for pregnancy loss across gestational periods in Holstein cattle under a Mexican intensive, temperate semi-arid production system.
Lammoglia-Villagómez MÁ, Avalos-Rosario II, Fletcher R, et al. · Vet Anim Sci 2026
- Procedural performance and safety of a helix locking tool for left bundle branch pacing: a prospective multicenter study.
Menéndez D, Vallès E, Del Castillo ÁM, et al. · J Interv Card Electrophysiol 2026
- The leader-trailer helix of pre-16S rRNA increases the speed and efficiency of 30S subunit biogenesis in Escherichia coli.
Warner BR, Fredrick K · RNA 2026
- A generalizable method for the purification and biophysical characterization of bacterial membrane receptors.
Bosetto F, Zacharopoulou M, Bycroft M, et al. · Protein Sci 2026
- Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database.
Rozza D, Poluzzi E, Antonazzo IC, et al. · Clin Drug Investig 2026
Also in development for Hepatitis D, Chronic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.